
# Modelling seasonal influenza in England:

# Approaches to capture immunity propagation



**Edward Hill**<sup>1</sup>, S. Petrou<sup>2</sup>, S. de Lusignan<sup>2,3</sup>, I. Yonova<sup>3,4</sup>, Matt Keeling<sup>1</sup> <sup>1</sup>University of Warwick, UK. <sup>2</sup>University of Oxford, UK. <sup>3</sup>Royal College of General Practitioners, UK. <sup>4</sup>University of Surrey, UK.





Please feel free to contact me:

Edward.Hill@warwick.ac.uk







Take a picture to download the paper



# Propagation of seasonal influenza immunity is stronger if derived from natural infection.

#### 1. Motivation & aims

Seasonal influenza-related respiratory illnesses cause an estimated annual death toll of 291,000-646,000 people [1]. Influenza vaccination can offer some protection against infection for the individual, while contributing to reduced risk of ongoing transmission via establishment of herd immunity [2]. Transmission models connected to data, when interfaced with health economic evaluations, are a key tool to inform national influenza vaccine policy [3]. However, prior modelling studies have typically treated each season and each strain circulating within that season independently.


#### Study objectives:

- Develop a mathematical model incorporating a mechanism to link prior season epidemiological outcomes to immunity at the beginning of the following season;
- ii. Quantify contribution of differing sources of immunity propagation between years on seasonal influenza transmission dynamics in England, 2012/13 to 2017/18.


#### 2. Model overview

Non-age, multi-strain model, capturing the four strains targeted by the quadrivalent influenza vaccine: A(H1N1)pdm09, A(H3N2), B/Victoria, B/Yamagata.

Fig. 1: Model schematic. Process A (circled capitalised letters), propagation of immunity; process B, modulation of current influenza season virus susceptibility; process C, estimation of influenza case load; process D, ascertainment of cases.



#### 3. Immunity propagation model component



Propagated vaccine immunity related linearly to prior season vaccine efficacy:


 $c_m^y = 1 - \xi \alpha_m^{y-1}; \quad \xi \in (0,1)$ 

## 4. Transmission & observation model components

- Vaccination model: `Leaky' vaccine
- **Epidemiological model:** SEIR-type deterministic, ODEs (Fig. 3).
- Track incidence rate (per 100,000) of new strain m influenza infections in season y:

$$Z_m(y) = \left(\int_{y-1}^{y} \gamma_{1,m} (E_m^N + E_m^V) dt\right) \times 100,000.$$

Fig. 3: Transmission model schematic (for a single strain).




• Observation model - Estimate ascertainable influenza cases:  $Z_m^+(y) = \epsilon_y Z_m(y)$ .

## 5. Results: Parameter inference


Invoked an adaptive-population Monte Carlo ABC algorithm [4]. Prior season influenzal B cross-reactivity and carry over vaccine efficacy had little impact on immunity.

Fig. 4: Immunity propagation parameter posterior distributions, from 10,000



#### 6. Results: Goodness-of-fit

Fig. 5: Posterior predictive distributions for influenza positive GP consultations.



#### 7. Outlook

- Augment model with age structure.
- Couple transmission model with economic evaluation frameworks.
- Appraise cost-effectiveness of prospective seasonal influenza vaccine programmes.

## References

- - doi:10.1016/S0140-6736(17)33293-2. [2] RG Pebody et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-

[1] AD Iuliano et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018; 391 (10127): 1285-1300.

- age children, 2013/14 influenza season. Eurosurveillance. 2014;19(22):pii=20823. [3] M Baguelin, A Camacho, S Flasche, WJ Edmunds. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in
- [4] M Lenormand, F Jabot, G Deffuant. Adaptive approximate Bayesian computation for complex models. *Computational Statistics*.
- England and Wales: a cost-effectiveness study. *BMC Medicine*. 2015;**13**:236. doi: 10.1186/s12916-015-0452-y. 2013;**28**(6):2777-2796. doi: 10.1007/s00180-013-0428-3.

# Acknowledgements

We thank Simon de Lusignan, Ivelina Yonova and staff at the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) for granting use of RCGP RSC data. The GP consultation data resides with the RCGP RSC and are available via the RCGP RSC website (www.rcgp.org.uk/rsc). We acknowledge Stavros Petrou for helpful discussions. This work is independent research funded by the National Institute for Health Research (NIHR) (Policy Research Programme, Infectious Disease Dynamic Modelling in Health Protection, 027/0089). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.